TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38265467

Group type: EXPERIMENTAL
Intervention: MDD with suicidality
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: MDD without suicidality
Number of subjects: 39

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 39
Study: 38265478

Group type: EXPERIMENTAL
Intervention: Obstetric patient navigation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard postpartum care (implied control)
Number of subjects: 0
Study: 38265633

Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 1485

Group type: COMPARATOR
Intervention: Axitinib
Number of subjects: 1485
Study: 38265781

Group type: EXPERIMENTAL
Intervention: REThink Online System (gamified assessment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38265815

Group type: EXPERIMENTAL
Intervention: Belatacept
Number of subjects: 311

Group type: COMPARATOR
Intervention: CNI
Number of subjects: 311
Study: 38265835

Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg, once daily)
Number of subjects: 1151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1151
Study: 38265847

Group type: EXPERIMENTAL
Intervention: WayToServe training and WayToServe Plus
Number of subjects: 180

Group type: COMPARATOR
Intervention: WayToServe training only
Number of subjects: 180
Study: 38266104

Group type: EXPERIMENTAL
Intervention: Pexidartinib (CSF-1R inhibitor)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Durvalumab (anti-PD-L1)
Number of subjects: 47
Study: 38266154

Group type: EXPERIMENTAL
Intervention: efmoroctocog alfa (rFVIIIFc)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-titer inhibitor progression to high-titer inhibitor
Number of subjects: 0
Study: 38266332

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for anxiety and obsessive-compulsive disorders, 12 sessions
Number of subjects: 27

Group type: COMPARATOR
Intervention: Behavioral and self-report measures of SFA
Number of subjects: 27
Study: 38266482

Group type: EXPERIMENTAL
Intervention: Post-trigger LH levels < 22 IU/L
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Basal LH levels < 4 IU/L
Number of subjects: 224

Group type: COMPARATOR
Intervention: Post-trigger LH levels above 15 IU/L
Number of subjects: 224
Study: 38266575

Group type: EXPERIMENTAL
Intervention: Lateropulsion attenuation
Number of subjects: 106
Study: 38266683

Group type: EXPERIMENTAL
Intervention: Apremilast (20 or 30 mg BID based on weight)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Apremilast
Number of subjects: 245
Study: 38267024

Group type: EXPERIMENTAL
Intervention: Oral anticoagulant therapy (OAC)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Healthcare provider involvement
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Patient knowledge and psychological factors
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Integrated, patient-centred approach
Number of subjects: 61
Study: 38267096

Group type: EXPERIMENTAL
Intervention: CRE infection
Number of subjects: 1175

Group type: COMPARATOR
Intervention: CSE infection
Number of subjects: 1175

Group type: COMPARATOR
Intervention: Non-infected patients
Number of subjects: 1175

Group type: COMPARATOR
Intervention: CRE infection vs CSE infection
Number of subjects: 1175

Group type: COMPARATOR
Intervention: CRE infection vs Non-infected patients
Number of subjects: 1175

Group type: COMPARATOR
Intervention: CRE infection vs CSE infection (after adjustment)
Number of subjects: 1175

Group type: COMPARATOR
Intervention: CRE infection vs Non-infected patients (after adjustment)
Number of subjects: 1175

Group type: COMPARATOR
Intervention: CRE infection vs CSE infection (with treatment-related variables)
Number of subjects: 1175
Study: 38267105

Group type: EXPERIMENTAL
Intervention: Subclinical synovitis resolution
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Subclinical synovitis persistence
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Good prognostic factors for resolution
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: ROC curve analysis
Number of subjects: 90
Study: 38267108

Group type: EXPERIMENTAL
Intervention: M/T FDC
Number of subjects: 187

Group type: COMPARATOR
Intervention: macitentan
Number of subjects: 187

Group type: COMPARATOR
Intervention: tadalafil
Number of subjects: 187
Study: 38267144

Group type: EXPERIMENTAL
Intervention: IVI-guided PCI
Number of subjects: 4611

Group type: EXPERIMENTAL
Intervention: Present IVI-guided PCI
Number of subjects: 4611

Group type: COMPARATOR
Intervention: Angiography-guided PCI
Number of subjects: 4611
Study: 38267149

Group type: EXPERIMENTAL
Intervention: Ultrasound measurements of QRF area and thickness
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Ultrasound measurements of QRF thickness
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Ultrasound measurements of QRF area
Number of subjects: 143
Study: 38267188

Group type: EXPERIMENTAL
Intervention: Glenzocimab 1000 mg
Number of subjects: 166

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study: 38267220

Group type: EXPERIMENTAL
Intervention: Foot length measurement (FL) with a cut-off of ≤7.6 cm
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Foot length measurement (FL) with a cut-off of ≤7.5 cm
Number of subjects: 336
Study: 38267239

Group type: EXPERIMENTAL
Intervention: Time-restricted eating (TRE) combined with supervised exercise
Number of subjects: 184

Group type: COMPARATOR
Intervention: Time-restricted eating (TRE) alone
Number of subjects: 184

Group type: COMPARATOR
Intervention: Supervised exercise alone
Number of subjects: 184

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 184
Study: 38267243

Group type: EXPERIMENTAL
Intervention: Ferric derisomaltose infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral ferrous succinate
Number of subjects: 0
Study: 38267245

Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBM) at a dose of 7.5 J/cm²
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mobile health education (mHealth)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 60
Study: 38267330

Group type: EXPERIMENTAL
Intervention: 20-valent pneumococcal conjugate vaccine (PCV20)
Number of subjects: 1421

Group type: COMPARATOR
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13)
Number of subjects: 1421

Group type: COMPARATOR
Intervention: 23-valent polysaccharide vaccine (PPSV23)
Number of subjects: 1421

Group type: EXPERIMENTAL
Intervention: PCV20
Number of subjects: 1421
Study: 38267484

Group type: EXPERIMENTAL
Intervention: Genome-wide polygenic score for higher BMI
Number of subjects: 1210
Study: 38267496

Group type: EXPERIMENTAL
Intervention: Neonatal Fc receptor inhibitors
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Complement inhibitors
Number of subjects: 62

Group type: COMPARATOR
Intervention: Industry-sponsored trials
Number of subjects: 62

Group type: COMPARATOR
Intervention: Trials releasing results
Number of subjects: 62

Group type: COMPARATOR
Intervention: Phase 3 trials
Number of subjects: 62
Study: 38267533

Group type: EXPERIMENTAL
Intervention: Low-GI Mediterranean diet
Number of subjects: 160

Group type: COMPARATOR
Intervention: High-GI Mediterranean diet
Number of subjects: 160
Study: 38267603

Group type: EXPERIMENTAL
Intervention: LSVT® BIG
Number of subjects: 32

Group type: COMPARATOR
Intervention: Progressive Structured Mobility Training
Number of subjects: 32
Study: 38267634

Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tumour subpopulations associated with favourable prognosis and trastuzumab sensitivity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tumour subpopulation associated with poor prognosis and trastuzumab resistance
Number of subjects: 0
Study: 38267692

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study: 38267790

Group type: EXPERIMENTAL
Intervention: Ritlecitinib 50-mg capsules
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ritlecitinib 100-mg capsules
Number of subjects: 0
Study: 38267801

Group type: EXPERIMENTAL
Intervention: Invasive Escherichia coli disease (IED)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Antimicrobial resistance (AMR) rates of E. coli isolates
Number of subjects: 240
Study: 38267837

Group type: EXPERIMENTAL
Intervention: Health systems-level intervention alone
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Health systems-level intervention combined with shared decision-making aid
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned, but implied as standard care without the interventions)
Number of subjects: 33
Study: 38267890

Group type: EXPERIMENTAL
Intervention: BENIT program
Number of subjects: 6
Study: 38267889

Group type: EXPERIMENTAL
Intervention: EPIMix (one-minute multi-contrast MRI)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: EPIMix
Number of subjects: 15

Group type: COMPARATOR
Intervention: CT
Number of subjects: 15

Group type: COMPARATOR
Intervention: EPIMix and CT
Number of subjects: 15
Study: 38267942

Group type: EXPERIMENTAL
Intervention: Allopurinol administered immediately after birth
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38267987

Group type: EXPERIMENTAL
Intervention: High-density lipoprotein cholesterol (HDL-C) levels
Number of subjects: 20351
Study: 38268013

Group type: EXPERIMENTAL
Intervention: Maternal depression screening using the Patient Health Questionnaire (PHQ-9)
Number of subjects: 101
Study: 38268015

Group type: EXPERIMENTAL
Intervention: Pictorial information about subclinical atherosclerosis with personalized, colour-coded and age-related risk communication strategy and motivational conversation
Number of subjects: 1749
Study: 38268043

Group type: EXPERIMENTAL
Intervention: Virtual reality-based cognitive remediation programme
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 66
Study: 38268101

Group type: EXPERIMENTAL
Intervention: Deucravacitinib 6 mg once daily
Number of subjects: 74
Study: 38268156

Group type: EXPERIMENTAL
Intervention: Metformin (0.5 g three times per day)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 140
Study: 38268157

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Secukinumab (150 mg to 300 mg dose escalation)
Number of subjects: 397

Group type: COMPARATOR
Intervention: Any secukinumab group
Number of subjects: 397

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 397
Study: 38268221

Group type: EXPERIMENTAL
Intervention: Maternal vaginal and rectal microbiomes during the last trimester
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Neonatal microbiome at birth
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Neonatal microbiome 2-3 days postnatally
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Neonatal microbiomes in infants delivered by cesarean section
Number of subjects: 30
Study: 38268522

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 40
Study: 38268525

Group type: EXPERIMENTAL
Intervention: On FI.RE. accelerated framework
Number of subjects: 76

Group type: COMPARATOR
Intervention: Traditional OFR framework
Number of subjects: 76
Study: 38268535

Group type: EXPERIMENTAL
Intervention: Benralizumab
Number of subjects: 632
Study: 38268678

Group type: EXPERIMENTAL
Intervention: Canteen menus targeted to the individuals' nutritional and sensory needs
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standardized meal evaluation forms
Number of subjects: 22
Study: 38268752

Group type: EXPERIMENTAL
Intervention: Batoclimab 680 mg QW for 12 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Batoclimab 340 mg QW for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Batoclimab 340 mg QW or Q2W for maintenance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo for maintenance
Number of subjects: 0
Study: 38269045

Group type: EXPERIMENTAL
Intervention: Customized silicone digital orthoses plus specialized nurse-administered foot care
Number of subjects: 60

Group type: COMPARATOR
Intervention: Specialized nurse-administered foot care (Control Group)
Number of subjects: 60
Study: 38269046

Group type: EXPERIMENTAL
Intervention: Pharmaceutical consultation at hospital
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Pharmaceutical consultation at community pharmacy
Number of subjects: 226

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 226
Study: 38269049

Group type: EXPERIMENTAL
Intervention: COVID-19 convalescent plasma (CCP) therapy
Number of subjects: 281

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281
Study: 38269252

Group type: EXPERIMENTAL
Intervention: Maternal fasting glucose
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Maternal 2-hour glucose
Number of subjects: 105
Study: 38269269

Group type: EXPERIMENTAL
Intervention: recombinant human annexin A5 (SY-005)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38269302

Group type: EXPERIMENTAL
Intervention: Post-COVID-19 condition (PCC)
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Mild PCC
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Hospitalized PCC
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: ICU-PCC
Number of subjects: 368

Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 368
Study: 38269534

Group type: EXPERIMENTAL
Intervention: Telephone health coaching with remote exercise monitoring (TeGeCoach; n = 994)
Number of subjects: 1982

Group type: COMPARATOR
Intervention: Routine care (n = 988)
Number of subjects: 1982
Study: 38270079

Group type: EXPERIMENTAL
Intervention: Primary aldosteronism (PA) with ARR ≥ 1.0
Number of subjects: 0

Group type: COMPARATOR
Intervention: Essential hypertension with ARR ≥ 1.0
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CVD risk based on ARR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ARR cutoff setting
Number of subjects: 0
Study: 38270182

Group type: EXPERIMENTAL
Intervention: S-LMA
Number of subjects: 510
Study: 38270219

Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 0
Study: 38270814

Group type: EXPERIMENTAL
Intervention: Patient-physician communication regarding fatigue
Number of subjects: 1179

Group type: EXPERIMENTAL
Intervention: Chemotherapy, radiotherapy, or immunotherapy
Number of subjects: 1179

Group type: EXPERIMENTAL
Intervention: Older age and major depression
Number of subjects: 1179

Group type: EXPERIMENTAL
Intervention: Communication barriers
Number of subjects: 1179

Group type: EXPERIMENTAL
Intervention: Physician appreciation and handling of fatigue-related questions
Number of subjects: 1179
Study: 38270822

Group type: EXPERIMENTAL
Intervention: Navitoclax 150 mg daily plus Sorafenib 400 mg twice daily
Number of subjects: 25

Group type: COMPARATOR
Intervention: Navitoclax alone
Number of subjects: 25
Study: 38270954

Group type: EXPERIMENTAL
Intervention: FFR-guided PCI
Number of subjects: 562

Group type: COMPARATOR
Intervention: Angiography-guided PCI
Number of subjects: 562
Study: 38271019

Group type: EXPERIMENTAL
Intervention: TranS-C group treatment
Number of subjects: 152
Study: 38271079

Group type: EXPERIMENTAL
Intervention: BMI + SFAS
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: BMI + RT
Number of subjects: 132

Group type: COMPARATOR
Intervention: BMI + SFAS and BMI + RT
Number of subjects: 132
Study: 38271299

Group type: COMPARATOR
Intervention: Informational counselling (IC) only
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: IC with hearing aid fitting
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: IC with individualized music stimulation for 12 months
Number of subjects: 38
Study: 38271308

Group type: EXPERIMENTAL
Intervention: Oral Assessment Guide (OAG) assessment
Number of subjects: 88

Group type: COMPARATOR
Intervention: Patients 60 months or younger
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Use of diuretics
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Frequency of oral care
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Glasgow Coma Scale score
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Artificial respiration
Number of subjects: 88
Study: 38271311

Group type: EXPERIMENTAL
Intervention: Endotracheal suctioning
Number of subjects: 32
Study: 38271320

Group type: EXPERIMENTAL
Intervention: Active VR
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Passive VR
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard-of-care
Number of subjects: 90
Study: 38271621

Group type: EXPERIMENTAL
Intervention: R-CHOP followed by (R)-ICE
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: R-CHOP followed by (R)-ICE (propensity score-matched patients from MSK)
Number of subjects: 151

Group type: COMPARATOR
Intervention: R-CHOP (matched MER cohort)
Number of subjects: 151
Study: 38271925

Group type: EXPERIMENTAL
Intervention: Rivoceranib 685 mg once daily (Part 2)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Rivoceranib 805 mg once daily (Part 3)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Rivoceranib (Part 1)
Number of subjects: 61
Study: 38272050

Group type: EXPERIMENTAL
Intervention: Individualised short-course antibiotic treatment (≤7 days, as short as 3-5 days)
Number of subjects: 461

Group type: COMPARATOR
Intervention: Usual care (≥8 days, with precise durations determined by primary clinicians)
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Short-course treatment
Number of subjects: 461

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 461
Study: 38272116

Group type: EXPERIMENTAL
Intervention: TBRI Caregiver Curriculum, TBRI Youth & Young Adult Curriculum, TBRI Nurture Groups (delivered while youth are in residential facilities)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TBRI Family Coaching Curriculum (delivered after youth transition home)
Number of subjects: 0
Study: 38272118

Group type: EXPERIMENTAL
Intervention: Disclosing Recovery intervention
Number of subjects: 50

Group type: COMPARATOR
Intervention: Comparator condition (attention-control)
Number of subjects: 50
Study: 38272247

Group type: EXPERIMENTAL
Intervention: Adults with ILD
Number of subjects: 112

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 112
Study: 38272046

Group type: COMPARATOR
Intervention: Intravenous immunoglobulin (2 g/kg, single dose)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Methylprednisolone (10 mg/kg per day for 3 consecutive days)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Tocilizumab (12 mg/kg for patients <30 kg; 8 mg/kg for patients ≥30 kg, max 800 mg)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Anakinra (2 mg/kg once per day for patients ≥10 kg)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Usual care (no additional treatments)
Number of subjects: 237
Study: 38272376

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (in QUEST)
Number of subjects: 0
Study: 38272373

Group type: EXPERIMENTAL
Intervention: Dupilumab treatment in patients with biallelic pathogenic FLG variants
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Dupilumab treatment in patients with monoallelic pathogenic FLG variants or wild-type alleles
Number of subjects: 285
Study: 38272375

Group type: EXPERIMENTAL
Intervention: dupilumab 100/200 mg by body weight or volume-matched placebo every 2 weeks for 52 weeks
Number of subjects: 408

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: dupilumab
Number of subjects: 408
Study: 38272383

Group type: EXPERIMENTAL
Intervention: PPOS protocol (Medroxyprogesterone 10 mg daily from start of ovarian stimulation until ovulation trigger)
Number of subjects: 784

Group type: COMPARATOR
Intervention: Antagonist protocol (Antagonist 0.25 mg daily from the sixth day of ovarian stimulation until ovulation trigger)
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: PPOS protocol (per-protocol analysis)
Number of subjects: 784

Group type: COMPARATOR
Intervention: Antagonist protocol (per-protocol analysis)
Number of subjects: 784
Study: 38272391

Group type: EXPERIMENTAL
Intervention: Suturelysis after trabeculectomy
Number of subjects: 15
Study: 38272555

Group type: EXPERIMENTAL
Intervention: High-cholesterol (600 mg)/low-saturated fat (6%) (egg) diet
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Low-cholesterol (300 mg)/high-saturated fat (12%) (egg free) diet
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control diet that is high in both cholesterol (600 mg) and saturated fat (12%)
Number of subjects: 52
Study: 38272561

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 32
Study: 38272571

Group type: EXPERIMENTAL
Intervention: Intravenous nerinetide
Number of subjects: 421

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 421
Study: 38272776

Group type: EXPERIMENTAL
Intervention: Remote delivery (RD) of weight management intervention
Number of subjects: 120

Group type: COMPARATOR
Intervention: Face-to-face (FTF) weight management intervention
Number of subjects: 120
Study: 38272892

Group type: EXPERIMENTAL
Intervention: Active cTBS intervention
Number of subjects: 39

Group type: COMPARATOR
Intervention: Sham cTBS intervention
Number of subjects: 39
Study: 38272958

Group type: EXPERIMENTAL
Intervention: RECO device
Number of subjects: 268
Study: 38273019

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP) administered as a monthly, 3-days course for three consecutive months
Number of subjects: 2340

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 2340

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 2340
Study: 38273044

Group type: EXPERIMENTAL
Intervention: Preoperative evaluation by echocardiography and inflammatory proteins
Number of subjects: 75
Study: 38273214

Group type: EXPERIMENTAL
Intervention: Clinical Treatment Score post-5 years (CTS5)
Number of subjects: 2114

Group type: EXPERIMENTAL
Intervention: Increasing continuous CTS5
Number of subjects: 2114

Group type: EXPERIMENTAL
Intervention: Prolonged endocrine therapy (ET) for high-risk patients
Number of subjects: 2114

Group type: EXPERIMENTAL
Intervention: CTS5
Number of subjects: 2114